Rgenta Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting | PR Newswire [Video]

, /PRNewswire/ — Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data will be presented from its lead program, RGT-61159, at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.

Title: RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Authors: Norman Lu, Patricia Soulard, Ibrahim Kay, Kai Li, Xiubin Gu, Heather Sadlish, Jay Lee, Mariam Elhawary, Michael Rotelli, Sam Hasson, Thomas Wynn, Chris Yates, Zhiping Weng, Simon Xi and Travis Wager

Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Session Date and Time: December 9, 2024, 6:00 – 8:00 PM …